替莫唑胺(TZM)作为单一药剂,相对于对照,不显著增加mdian存活时间(MST)。值得注意的是,在施用100或200mg/kg替莫唑胺之前立即注射NU1025显著增加了对照组或仅用替莫唑胺治疗的组的寿命。当Temozolomide分次时,使用此方案获得的寿命增加(ILS)高于NU1025与单次注射替莫唑胺时的观察结果(生存曲线的统计比较:颅内NU1025 +替莫唑胺100 mg/kg×2对NU1025) +替莫唑胺200 mg/kg; P = 0.023)[1]。
SMILES
O=C(C1=C(N2C=N1)N=NN(C)C2=O)N
靶点
Autophagy;DNA Alkylator/Crosslinker
动物实验
小鼠[1]雄性B6D2F1(C57BL/6×DBA/2)小鼠用氯胺酮(100mg/kg)和甲苯噻嗪(5mg/kg)在0.9%NaCl溶液(10mL/kg腹膜内)中麻醉。然后使用0.1-mL玻璃微量注射器和27-gauge一次性针头,将L5178Y细胞(104 in 0.03 mL RPMI-1640)颅内注射,通过额骨的中间中间区域至2mm深度。为了评估肿瘤细胞生长,将脑固定在10%磷酸盐缓冲的甲醛中,沿轴平面切割组织切片(5μm),用苏木精 – 伊红染色,并通过光学显微镜分析。将替莫唑胺溶解于DMSO(40mg/mL)中,用盐水(5mg/mL)稀释,并在肿瘤注射后第2天以100mg/kg或200mg/kg腹膜内给药,通常用于体内临床前研究的剂量。由于替莫唑胺和PARP抑制剂诱导的细胞毒性可通过分次治疗方式改善,因此在选定的组中,总剂量为200 mg/kg替莫唑胺在第2天和第3天分为2剂100 mg/kg。
[1]. Tentori L, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002 Mar 15;99(6):2241-4.
[2]. Perazzoli G, et al. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. PLoS One. 2015 Oct 8;10(10):e0140131
规格
10mg 10mM*1mL in DMSO 50mg 100mg
是一种 DNA 烷基化 (DNA alkylating) 剂。也是一种促自噬 (autophagy) 和促凋亡剂 (apoptosis)。具有抗肿瘤和抗血管生成作用。
[1]. Siddiquee K, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6. [2]. Lin L, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene. 2009 Feb 19;28(7):961-72. [3]. Zhou C, et al. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. J Clin Invest. 2015 Apr;125(4):1692-702
NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) in promoting Hematopoietic stem cells (HSCs) expansion in both murine and human models.
纯度
>98%
储存/保存方法
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
NSC 624206 is an inhibitor of ubiquitin-activating enzyme (E1) that specifically blocks ubiquitin-thioester formation (IC50 = 13 µM) but has no effect on ubiquitin adenylation. Through this action, NSC 624206 prevents the ubiquitination and degradation of the tumor suppressor protein p27 in vitro.
纯度
≥95%
储存/保存方法
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
1.Ungermannova, D.,Parker, P.J.,Nasveschuk, C.G., et al. Identification and mechanistic studies of a novel ubiquitin E1 inhibitor. J. Biomol. Screen. 17(4), 421-434 (2012).
[1]. Veluthakal R, et al. NSC23766, a Known Inhibitor of Tiam1-Rac1 Signaling Module, Prevents the Onset of Type 1 Diabetes in the NOD Mouse Model. Cell Physiol Biochem. 2016;39(2):760-7. [2]. Song SJ, et al. Inhibition of Rac1 GTPase activity affects porcine oocyte maturation and early embryo development. Sci Rep. 2016 Oct 3;6:34415 [3]. Zhao L, et al. Rac1 modulates the formation of primordial follicles by facilitating STAT3-directed Jagged1, GDF9 and BMP15 transcription in mice. Sci Rep. 2016 Apr 6;6:23972 [4]. Wang Y, et al. Involvement of Rac1 signalling pathway in the development and maintenance of acute inflammatory pain induced by bee venom injection. Br J Pharmacol. 2016 Mar;173(5):937-50
[1]. Natarajan G, et al. Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol. 1999 Nov 15;58(10):1625-9.
[2]. Banerji U, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol. 2008 Oct;62(5):769-78.
[3]. Clark CC, et al. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Mol Cancer Ther. 2012 Sep;11(9):1948-58.
[4]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116.